Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: A placebo-controlled randomised trial

BMJ Open

Volumn 2, Issue 1, 2012, Pages

  Lotvall J ^a   Bakke, P S ^b   Bjermer, L ^c   Steinshamn, S ^d,e   Scott Wilson, C ^f   Crim, C ^f   Sanford, L ^g   Haumann, B ^g  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

^c Department of Respiratory Medicine and Allergology   (Sweden)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^f GLAXOSMITHKLINE   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE FUROATE; FLUTICASONE FUROATE PLUS VILANTEROL; GLUCOSE; POTASSIUM; UNCLASSIFIED DRUG; VILANTEROL;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEART RATE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; POWDER INHALER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; THORAX PAIN; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; VITAL SIGN;

EID: 84859029764     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000370     Document Type: Article

References (36)

1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006;27:188-207. (Pubitemid 43092683)
2. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. (Pubitemid 43180921)
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Guidelines on COPD Diagnosis, Prevention and Management. 2010. http://www.goldcopd.org (accessed Aug. 2011).
5. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-52.
6. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
7. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. (Pubitemid 41507533)
8. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:776-89.
9. Kardos P, Wencker M, Glaab T. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9. (Pubitemid 46115085)
10. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8.
11. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008;102:1099-108.
12. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
13. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310. (Pubitemid 32804122)
14. Procopiou PA, Barrett VJ, Bevan NJ. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem 2010;53:4522-30.
15. Barrett VJ, Emmons A, Ford AJ, et al. In vitro pharmacological characterisation of GW642444, a novel long acting β2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor CAMP Assays. Am J Respir Crit Care Med. 2010;181:A4451.
16. Morrison V, Sturton G, Barrett V, et al. Pharmacological characterisation of GW642444, a long-acting ß2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways. Am J Respir Crit Care Med 2010;181:A4453.
17. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-7. (Pubitemid 47358828)
18. Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011;670:244-51.
19. Kempsford RD, Norris V, Siederer SK. GW642444, a novel inhaled long-acting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients. Am J Respir Crit Care Med 2010;181:A4447.
20. Hanania N, Feldman G, Zachgo W, et al. Safety of vilanterol trifenatate (VI) in a COPD dose-ranging study. Eur Respir J 2010;36(Suppl 54):208s.
21. Lötvall J, Bakke P, Bjermer L, et al. Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients. Eur Respir J 2010;36(Suppl 54):1013s.
22. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax 2012;67:35-41.
23. Bleecker ER, Bateman ED, Busse W, et al. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010;36(Suppl 54):204s.
24. Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebocontrolled trial. Respir Res 2011;12:132.
25. Bleecker E, Bateman E, Busse W, et al. Consistently favorable safety profile of fluticasone furoate (FF), a once-daily (OD) inhaled corticosteroid (ICS), across a range of treatment steps in patients with uncontrolled asthma. Am J Respir Crit Care Med 2011;183:A1300.
26. Hanania N, Feldman G, Zachgo W, et al. Dose-related efficacy of vilanterol trifenatate (VI) in COPD. Eur Respir J 2010;36(Suppl 54):217s.
27. Sears MR. Adverse effects of ß-agonists. J Allergy Clin Immunol 2002;110:S322-8.
28. Salpeter SR, Omiston TM, Salpeter EE. Cardiovascular effects of β2-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-21. (Pubitemid 38796452)
29. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993;6:204-10. (Pubitemid 23074658)
30. Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-60.
31. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropiumdthe FDA's conclusions. N Engl J Med 2010;363:1097-9.
32. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-25.
33. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90.
34. Cazzola M, MacNee W, Martinez FJ, et al; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69.
35. Haney S, Hancox RJ. Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med 2005;99:566-71. (Pubitemid 40468503)
36. Hurst JR, Wedzicha JA. Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Med 2009;7:40.